Doctor explains: Cure or risk, should thalassemia patients opt for bone marrow transplant?

Thalassemia major, the most severe form of this inherited blood disorder, traps patients in a lifelong cycle of blood transfusions, iron chelation therapy and constant medical care. Globally, an estimated 1.3 million people live with severe or transfusion-dependent thalassemia, with the highest burden in South Asia, the Mediterranean, Southeast Asia and parts of West Asia.

While advances in transfusion support have improved survival, they do not eliminate dependence on treatment. Over time, repeated transfusions lead to iron overload, damaging vital organs such as the heart, liver and endocrine system, and adding to long-term health risks.

Bone marrow (hematopoietic stem cell) transplant offers a potential cure by replacing defective blood-forming cells with healthy donor cells. But the procedure is complex, costly and carries significant risks, including infections, graft failure and graft-versus-host disease. Access to a suitable donor further complicates the decision.

More from Health

At the same time, emerging gene therapies and newer drugs are beginning to reshape treatment options, though they remain expensive and limited in reach. This leaves families facing a difficult question: should they continue lifelong supportive care, or opt for a high-risk procedure that offers the possibility of a cure?

Firstpost spoke to Dr. Mahak Agarwal, Consultant – Transplantation and Cellular Therapy (AIBTraCT), Action Cancer Hospital (New Delhi) to understand the realities of thalassemia care, the role of bone marrow transplant, and what the future may hold.

________________________________________

Excerpts

How does long-term dependence on blood transfusions affect patients?

Dr Agarwal: Long-term transfusion dependence affects patients both physically and emotionally. While transfusions are life-sustaining, repeated transfusions lead to iron overload, where excess iron accumulates in organs such as the heart, liver and endocrine glands, causing serious complications.

Equally important is the psychological burden. Patients often grow up around hospital schedules, restrictions and constant awareness of their condition. Education, employment and social life can be affected due to fatigue, growth delays and chronic illness.

________________________________________

What is thalassemia and why does it affect haemoglobin production?

Dr Agarwal: Thalassemia is a genetic blood disorder caused by mutations in genes responsible for producing globin chains, which are essential components of haemoglobin. Haemoglobin carries oxygen throughout the body.

Each person inherits two copies of these genes—one from each parent. If both copies are defective, the body cannot produce normal haemoglobin, leading to fragile red blood cells and severe anaemia within the first few months of life. These patients require lifelong transfusions.

If only one gene is affected, the person is a carrier (thalassemia minor) and usually has no symptoms. This condition is typically detected through routine blood tests.

________________________________________

When is bone marrow transplant considered as a treatment option?

Dr Agarwal: Bone marrow transplant (BMT) is the only established curative treatment for beta thalassemia major. Unlike many other blood disorders, BMT should be considered early in the disease course.

Outcomes are best in younger patients with well-controlled disease and access to an HLA-matched sibling donor. While transfusion and chelation therapy improve survival, they are supportive treatments and are associated with long-term complications.

Advances have also made transplants from partially matched donors possible, especially within clinical settings.

________________________________________

Is bone marrow transplant truly a cure for thalassemia?

Dr Agarwal: BMT can be curative if donor stem cells successfully engraft and function normally. In such cases, patients can maintain normal haemoglobin levels without transfusions, and some organ damage caused by iron overload may improve.

However, the process is complex. It involves replacing diseased bone marrow with healthy donor cells after intensive chemotherapy. The patient’s body must accept these cells to avoid rejection.

In simple terms, it is about the donor cells adapting to the patient’s body and functioning effectively.

________________________________________

What are the major risks associated with bone marrow transplant?

Dr Agarwal: BMT is an intensive procedure. In the short term, patients are highly vulnerable to infections as the immune system takes time to recover.

Graft-versus-host disease (GvHD), where donor immune cells attack the patient’s tissues, is one of the most serious complications. Graft failure and organ toxicity from conditioning therapy are also concerns.

In the long term, some patients may face fertility issues or other health complications. However, with advances in transplant protocols and supportive care, outcomes have improved significantly.

________________________________________

How difficult is it to find a suitable donor in India?

Dr Agarwal: The chance of finding a fully matched sibling donor is about 1 in 4. However, only 10–20% of patients actually have such a donor within the family.

In Western countries, large donor registries increase the chances of finding unrelated matches. In India, this probability remains much lower.

This has led to the growing use of haploidentical (half-matched) family donors, such as parents. With recent advances, outcomes from such transplants have improved significantly, making curative treatment more accessible.

________________________________________

What does recovery after a successful transplant look like?

Dr Agarwal: Recovery takes several months. Physically, patients need time to regain strength as the immune system rebuilds. Strict infection control, nutrition and regular follow-up are critical.

Emotionally, the transition can be significant. Patients and families move from a life centred on transfusions to cautious optimism. Psychological support plays an important role during this phase.

Long-term monitoring is essential to ensure graft stability and overall health.

________________________________________

Why do families delay or hesitate to opt for transplant?

Dr Agarwal: A common misconception is that BMT is extremely risky and should be considered only as a last resort. While risks exist, this view often ignores the long-term complications of lifelong transfusion dependence.

Many families also misunderstand the procedure, thinking it is similar to major surgery. Fear of the unknown and lack of awareness about improved outcomes contribute to delays.

Clear, transparent counselling is crucial to help families make informed decisions based on a balanced understanding of risks and benefits.

________________________________________

How do you see the future of thalassemia treatment evolving?

Dr Agarwal: Gene therapy is a promising approach for genetic disorders like thalassemia. Advances in genetic engineering have made it a clinical reality in some regions.

However, these therapies remain extremely expensive and inaccessible to most patients globally. Some newer drugs aim to reduce transfusion needs, but results have been mixed.

For now, bone marrow transplant remains the only widely available curative option. In the future, as costs reduce, gene therapy may become more accessible.